Table 7.

Society guidelines for chemoradiation in the management of T1-T2 N1 oropharyngeal cancer.

ASTRO Clinical Practice guideline 99	“After a careful discussion of patient preferences and the limited evidence supporting its use, concurrent systemic therapy may be delivered to patients with T1-T2 N1 OPSCC receiving definitive RT who are considered at particularly significant risk for locoregional recurrence. (Conditional, LQE, 100%)”
	“However, certain patients with T1–2 N1 OPSCC who are considered at particularly significant risk for locoregional recurrence may receive concurrent systemic therapy, because the absolute benefit of combined modality therapy may justify its toxicities in this population.”
ACR Appropriateness Criteria 100	“Patients with T1–2 N1–2aM0 disease can receive radiation, chemoradiation, or transoral surgery with neck dissection and appropriate adjuvant therapy.”
AHNS guidelines 101	“Nevertheless, treatment strategies remain the same despite HPV status. Further research is necessary to determine the safety and efficacy of altering the management for patients with HPV‐positive HNSCC with respect to the new staging.”
ASCO guidelines 102	“Concurrent systemic therapy may be delivered to patients with T1-T2 N1 OPSCC receiving definitive radiotherapy who are considered at particularly significant risk for locoregional recurrence, after a careful discussion of patient preferences and the limited evidence supporting its use (Recommendation strength: conditional, Quality of evidence: low).”